A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you capture the savings depends on a coverage question most people do not realize they are answering.

Medicare spent years refusing to pay for GLP-1 drugs prescribed only for weight loss. A new program called the GLP-1 Bridge changes that, although only partway and only for a limited time.

What The Bridge Actually Offers

The Bridge is a time-limited federal demonstration that runs from July 1, 2026 through December 31, 2027. Eligible Medicare Part D members can fill certain weight-loss GLP-1 medications for a $50 copay per 30-day supply. The launch list covers Wegovy in both the injection and tablet forms and Zepbound in the KwikPen version.

Those two brands point straight at companies investors already track. Wegovy is made by Novo Nordisk A/S (NYSE:NVO), which partnered with the government on the rollout, and Zepbound belongs to Eli Lilly and Co. (NYSE:LLY). A wave of newly subsidized Medicare demand lands on the drugmakers’ flagship obesity products, so the demonstration is as much a revenue story as a coverage story.

The Eligibility Line That Decides Your Price

The Bridge was built for people who want a GLP-1 solely for weight loss and have no other route to coverage, so the rules exclude some patients you might expect to qualify first. According to a Benzinga breakdown of the program, eligibility centers on a body mass index of 35 or higher, plus some patients with lower BMIs who also carry obesity-related conditions such as prediabetes or a history of stroke, heart attack, or blocked arteries.

You are not eligible for the Bridge if you already receive a GLP-1 through your regular Part D plan, and you are not eligible if you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease. That sounds backward until you see the logic. Those conditions already open a different and often stronger door, because Medicare Part D has covered GLP-1s for years when they treat a recognized medical condition rather than weight alone.

The result is a two-track system. On the first track, a qualifying diagnosis such as type 2 diabetes gets a drug like Ozempic covered through a normal Part D plan as diabetes treatment. On the second track, the Bridge catches people who lack one of those diagnoses and simply need help with weight. This also explains why Ozempic never appears on the Bridge list, since it is a diabetes drug that flows through the first track.

The Copay Catch Worth Reading Twice

A $50 copay sounds simple, and the fine print is where it stops being simple. That $50 does not count toward your deductible, and it does not count toward your annual out-of-pocket maximum. The money you spend on a Bridge medication sits outside the rest of your drug spending math, so it does not help you reach the cap that would otherwise start protecting you on everything else.

For most people that detail is a footnote, because $50 a month still crushes a $400 cash bill. For someone with a long list of prescriptions who was counting on every dollar to push them toward their out-of-pocket ceiling, the exclusion matters.

What It Means For Your Money

The math is direct. Paying cash at $350 a month costs $4,200 a year, while the Bridge at $50 a month costs $600, a swing of roughly $3,600 back into your budget for as long as the demonstration runs and you remain eligible.

If you qualify for the standard Part D route instead, your cost depends on your plan, and you also gain the 2026 change that caps total out-of-pocket drug spending at $2,100 for the year. Understanding which track fits you is worth real money before you assume the worst or, just as costly, assume Medicare still refuses to help at all.

The Investor Angle Behind The Rollout

For readers who hold healthcare names, the Bridge cuts two ways. Subsidized access should lift prescription volume for Novo Nordisk and Eli Lilly among a Medicare population that was mostly priced out, and that is a clear tailwind for two stocks whose valuations already lean heavily on obesity demand. Yet the government negotiated the discount, so higher volume arrives alongside lower per-prescription economics, and the entire arrangement carries an expiration date at the end of 2027 unless Washington extends it.

The rollout also creates work for the plans that administer it. CMS contracted Humana Inc. (NYSE:HUM) to process approvals, with requests expected to clear within 72 hours once a provider certifies that a patient meets the requirements. That administrative role is a reminder that a single policy change ripples across drugmakers, insurers, and pharmacy benefit operations at the same time.

What Smart Enrollees Do Before 2027 

Medicare moved from a flat refusal to a narrow yes, priced at $50, available to a specific group, and scheduled to close at the end of 2027. For the right person, the Bridge is a strong deal that should not be left on the table, and the smart move is to confirm which of the two coverage tracks applies before building a budget around a temporary price.

For investors, the same demonstration that helps patients also feeds demand for Novo Nordisk and Eli Lilly while introducing pricing and duration risk that belongs in any thesis. None of this is investment advice, and anyone weighing these stocks or their own coverage should confirm the current details with CMS, their Part D plan, and their own research before acting.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.